In an article published very recently in Pediatric Blood and Cancer by the COG entitled : A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic ewing sarcoma family of tumors: A Children’s Oncology Group (COG) phase II study (NCT00061893) that aimed at determining the feasibility of the combination of metronomic chemotherapy with celecoxib and vinblastine together with standard therapy for patients with metastatic Ewing sarcoma (ES), at obtaining preliminary outcome data.
35 patients with metastatic ES Have been included
The authors, Judy L. Felgenhauer and al. shown that :
1) while an OS advantage was not observed when compared to historical controls, the 2-year event-free survival of patients with pulmonary metastases only was better than expected at 71%.
2) the addition of the metronomic agents vinblastine and celecoxib to standard therapy for EWING sarcoma is feasible. However, high rates of pulmonary and bladder toxicity have been observed possibly due to the combination of radiation therapy and metronomic vinblastine/celecoxib. These findings suggest that the celecoxib/vinblastine may act as radiosensitizers.
The full text article can be read here